Navigation Links
InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
Date:2/16/2011

BRISBANE, Calif., Feb. 16, 2011 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the fourth quarter and full year ended December 31, 2010.

InterMune reported net income for the fourth quarter of 2010 of $206.1 million, or $3.34 per diluted share, compared with a net loss of $28.6 million, or $0.62 per diluted share, in the fourth quarter of 2009. Net income for the full year 2010 was $122.4 million, or $2.13 per diluted share, compared with a net loss of $116.0 million, or $2.62 per diluted share, in 2009.

Results for the fourth quarter and full year 2010 include proceeds of $175.0 million from the sale of danoprevir in October 2010 and the accelerated recognition of approximately $57.3 million of remaining deferred revenue in connection with the termination of the 2006 Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd. (Roche) collaboration agreement.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "Our financial results in 2010 were driven by the sale of our rights to danoprevir to Roche, which enabled us to end the year with $295 million in cash and cash equivalents and provided the financial resources to independently maximize the world-wide value of pirfenidone. In December of 2010 we announced the adoption of a positive opinion by European regulatory authorities for the marketing authorization of Esbriet™ (pirfenidone) and we expect Esbriet to soon become the first therapy approved for the treatment of IPF patients in Europe. Regarding the U.S., we announced in January of 2011 our plan to conduct a Phase 3 study toward the potential U.S. FDA approval of Esbriet for the more than 100,000 Americans who suffer from IPF."

Recent Clinical Development, Business Highlights and Upcoming MilestonesEsbriet™ (pirfenidone):

  • InterMune reported on Dec
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
    2. InterMune Announces Start of Phase 1b Trial of ITMN-191
    3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
    4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
    5. InterMune Announces Progress on Pirfenidone in IPF
    6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
    7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
    8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
    9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
    10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
    11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/14/2014)... July 14, 2014  Remedy Informatics, the leading ... delivery and life sciences research, announced that it ... (NPF) to build the first-ever national patient registry ... and pancreatitis. "The National Pancreas Foundation ... that thoughtful and committed organizations can effect upon ...
    (Date:7/14/2014)... DIEGO , July 14, 2014  More than any ... their smartphones and tablet computers -- but their eyes don,t. ... have never needed before, and the eye has not evolved ... and what our eyes can do comfortably often results in ... collectively known as Digital Eye Strain. Now ZEISS has invented ...
    (Date:7/14/2014)... , July 14, 2014  Celsion Corporation (NASDAQ: ... today that the Company will ring the NASDAQ Stock Market ... New York, NY . ... of the Celsion and EGEN management teams will participate in ... pm ET.  A live webcast will be available at ...
    Breaking Medicine Technology:Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 3New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014 2Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014 3
    ... Feb. 22, 2011 Delcath Systems, Inc. (Nasdaq: ... received a "refusal to file" letter from the U.S. ... Application (NDA) for its proprietary chemosaturation system used in ... liver through the percutaneous intra-arterial administration of melphalan hydrochloride. ...
    ... Va., Feb. 21, 2011 MicroAire ... endoscopic treatment for carpal tunnel syndrome.  MicroAire,s new ... and blade assembly that allows surgeons to treat ... the patient,s wrist – thereby avoiding full open-hand ...
    Cached Medicine Technology:Delcath Systems Receives Refusal to File Letter From FDA 2Delcath Systems Receives Refusal to File Letter From FDA 3Delcath Systems Receives Refusal to File Letter From FDA 4MicroAire Introduces New SlimLine™ ECTR Cannula 2
    (Date:7/14/2014)... 2014 Follow us ... chromatography or UPLC is a new and ... that involves the use of extremely small-sized ... chromatographic compounds. This highly sensitive qualitative and ... analysis of chromatography samples. UPLC functions on ...
    (Date:7/14/2014)... Skin M.D. by ... on Monday, July 14th, located at 45 East ... last all week through Saturday, July 19th, with ... welcomed to attend. The business is owned by ... anti-aging, weight loss services, and sells high-end industry ...
    (Date:7/14/2014)... KeyPoint Credit Union is teaming up with ... and one-mile family fun walk. The run begins inside ... finishes inside Levi’s® Stadium. , Over the past five ... Mission City Community Fund. All proceeds benefit education, seniors ... athletes, part-time pavement-pounders and walkers are invited to help ...
    (Date:7/14/2014)... (PRWEB) July 14, 2014 T.E.N., ... relationship-marketing firm, announced today that nominations will be ... 2014 Information Security Executive® (ISE®) North America Awards. ... of the Year, which recognizes executives who have ... risk management, data-asset protection, regulatory compliance, privacy and ...
    (Date:7/14/2014)... Many people are unhappy with their jawline. ... reduce a “double chin.” A new product that ... go under the knife. Jawflex is a double chin ... tightening the skin in that area and reducing the ... for facial exercise, double chin elimination and sagging jowls. ...
    Breaking Medicine News(10 mins):Health News:Need for Faster Sample Analysis Drives Demand for UPLC, According to New Trend Report Published by Global Industry Analysts, Inc. 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 2Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2
    ... linked to hypertension years later, study finds , MONDAY, ... and Afghanistan who go into combat are more likely ... than those who serve in supporting roles, a new ... appeared to be a unique risk factor for newly ...
    ... Surging obesity rates have reversed gains, study finds , MONDAY, ... heart disease may be on the wane, experts say, with ... are now in the clear when it comes to heart ... bear much of the blame for the downturn, the researchers ...
    ... Analysis notes tamoxifen, raloxifene can up chances of other ... Medications given to women at high risk for developing ... drugs carry other health risks, a new analysis suggests. ... at numerous published studies, including randomized clinical trials and ...
    ... Global meeting ... ... Scientists and Technologists, , ,WHAT: 21st International Radon Symposium , , ,WHEN: September 20-23, ... Station, , ,WHY: Radon remains a serious, global health threat and remains the ...
    ... 14 Misonix, Inc. (Nasdaq: MSON ), a ... Europe is used for the ablation of tumors and worldwide ... who wishes to remain anonymous, donated the majority of the ... NM, to purchase a SonicOne(R) Ultrasonic Wound Cleansing and Debridement ...
    ... , LOS ALTOS, Calif., Sept. 14 ... Higgins, PhD has been named Chief Operating ... as InteKrin,s Chief Scientific Officer after joining the Company earlier ... has had increasingly broad operational and strategic responsibility in key ...
    Cached Medicine News:Health News:Combat Exposure Tied to Chronic High Blood Pressure 2Health News:Most Adult Americans at Some Risk for Heart Disease 2Health News:Most Adult Americans at Some Risk for Heart Disease 3Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 2Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 3Health News:21st International Radon Symposium 2Health News:Misonix Equipment Funded By Anonymous Patient Donation 2Health News:Misonix Equipment Funded By Anonymous Patient Donation 3Health News:InteKrin Therapeutics Appoints Linda Slanec Higgins, PhD Chief Operating Officer 2
    ... Maxim knee system's curved-on-curved articulation maintains ... excellent sizing options for better patient ... alloy plasma spray porous coating, which ... own ArCom processed polyethylene is used ...
    ... posterior stabilized knee has an advanced ... flange mates with both resurfacing and ... precise, repeatable kinematics and fit with ... reduce wear. Constant cutting guide peg ...
    ... tricompartmental total knee prosthesis stems from many ... design and manufacturing technologies have been used ... as well as a favorable pressure distribution ... keep wear to a minimum. The inherent ...
    The Balanced Knee System provides instrumentation designed to achieve proper tissue balancing and alignment with user-friendly instrumentation that provides reproducible results....
    Medicine Products: